Article Text

Download PDFPDF

CD40 expression in renal cell carcinoma correlates with tumor apoptosis, CD8 T cell frequency and patient survival
  1. Jonathan M Weiss1,
  2. Gregory Alvord2,
  3. Octavio A Quinones2,
  4. Jimmy K Stauffer1 and
  5. Robert H Wiltrout1
  1. Aff1 grid.48336.3a0000000419368075Cancer and Inflammation ProgramNCI Frederick, CCR Frederick MD USA
  2. Aff2 grid.418021.e0000000405358394Statistical Consulting, DMSFrederick National Laboratory for Cancer Research Frederick MD USA

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Meeting abstracts


To investigate the relationship between tumor-associated CD40 expression, RCC patient survival and tumor stage.

Experimental design

The expression of CD40, TUNEL and CD8 in human renal cell carcinomas was analyzed by immunohistochemistry. Computer-assisted quantitation of protein expression was used to correlate results with patient survival and tumor stage.


We show for the first time that tumor-associated CD40 expression correlates with prolonged survival in RCC patients. CD40 also correlated with TUNEL and CD8 staining in tumor tissues. No correlation was observed between CD40 and tumor stage.


Our results suggest CD40 may be a prognostic biomarker indicative of prolonged RCC patient survival. Strategies that up-regulate CD40 expression in some RCC patients might lead to improved survival. The further development and use of agonistic CD40 antibodies for treatment of RCC is warranted.